

Thomas E Witzig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4414210/publications.pdf>

Version: 2024-02-01

504
papers

21,497
citations

13827

67
h-index

11030

137
g-index

506
all docs

506
docs citations

506
times ranked

17597
citing authors

#	ARTICLE	IF	CITATIONS
1	Axicabtagene Ciloleucef CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.	13.9	3,865
2	Randomized Controlled Trial of Yttrium-90 ⁹⁰ -Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 2453-2463.	0.8	1,069
3	Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 3262-3269.	0.8	624
4	Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20 ⁺ B-Cell Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 1999, 17, 3793-3803.	0.8	525
5	Phase II Trial of Single-Agent Temozolomide (CC-779) for Relapsed Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5347-5356.	0.8	509
6	Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 3688-3695.	0.8	320
7	Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non-Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 251-257.	0.8	319
8	Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 1066-1073.	0.8	304
9	MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. <i>Blood</i> , 2009, 113, 6669-6680.	0.6	297
10	Safety of Yttrium-90 Ibritumomab Tiuxetan Radioimmunotherapy for Relapsed Low-Grade, Follicular, or Transformed Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2003, 21, 1263-1270.	0.8	278
11	Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. <i>Cancer</i> , 2011, 117, 5058-5066.	2.0	277
12	Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 5404-5409.	0.8	259
13	Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Journal of Clinical Oncology</i> , 2013, 31, 3272-3278.	0.8	259
14	Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. <i>Blood</i> , 2002, 99, 4336-4342.	0.6	257
15	IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. <i>Journal of Clinical Investigation</i> , 2012, 122, 1271-1282.	3.9	243
16	Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. <i>Blood</i> , 2006, 107, 3378-3383.	0.6	230
17	Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma. <i>Cancer</i> , 2008, 113, 508-514.	2.0	220
18	Immunosuppressive CD14 ⁺ HLA-DR ^{low} monocytes in B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2011, 117, 872-881.	0.6	218

#	ARTICLE	IF	CITATIONS
19	Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 766-777.	3.3	210
20	Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving Chemotherapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 2606-2617.	0.8	199
21	A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2010, 85, 320-324.	2.0	197
22	Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin's Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 1103-1108.	0.8	187
23	Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4191-4198.	0.8	184
24	Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. <i>Blood</i> , 2004, 103, 4429-4431.	0.6	181
25	CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 ^{hi} T cells. <i>Blood</i> , 2007, 110, 2537-2544.	0.6	181
26	Long-Term Survival (10 Years or More) in 30 Patients With Primary Amyloidosis. <i>Blood</i> , 1999, 93, 1062-1066.	0.6	180
27	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.	2.0	180
28	Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. <i>Haematologica</i> , 2012, 97, 262-269.	1.7	175
29	Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. <i>Cancer</i> , 2007, 109, 1804-1810.	2.0	164
30	Ascorbic Acid in Cancer Treatment: Let the Phoenix Fly. <i>Cancer Cell</i> , 2018, 34, 700-706.	7.7	154
31	Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. <i>Blood</i> , 2009, 114, 2926-2935.	0.6	152
32	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines. <i>Mayo Clinic Proceedings</i> , 2010, 85, 824-833.	1.4	152
33	Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. <i>Lancet Oncology</i> , The, 2011, 12, 361-368.	5.1	151
34	Testicular lymphoma is associated with a high incidence of extranodal recurrence. , 2000, 88, 154-161.		147
35	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	9.4	147
36	Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. <i>Journal of Nuclear Medicine</i> , 2003, 44, 465-74.	2.8	145

#	ARTICLE	IF	CITATIONS
37	Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. <i>Blood</i> , 2009, 114, 2936-2944.	0.6	144
38	Treatment-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Patients Treated With Ibritumomab Tiuxetan Radioimmunotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 4285-4292.	0.8	142
39	Malignant B Cells Skew the Balance of Regulatory T Cells and TH17 Cells in B-Cell Non-Hodgkin's Lymphoma. <i>Cancer Research</i> , 2009, 69, 5522-5530.	0.4	140
40	Waldenström's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. <i>British Journal of Haematology</i> , 2000, 108, 737-742.	1.2	139
41	Proteomic analysis of mantle-cell lymphoma by protein microarray. <i>Blood</i> , 2005, 105, 3722-3730.	0.6	136
42	Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 118, 4053-4061.	0.6	136
43	A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017, 23, 4127-4137.	3.2	135
44	Phase II Trial of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Relapsed or Refractory Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 1408-1414.	0.8	132
45	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1317-1328.	0.8	132
46	Detection of circulating cytokeratin-positive cells in the blood of breast cancer patients using immunomagnetic enrichment and digital microscopy. <i>Clinical Cancer Research</i> , 2002, 8, 1085-91.	3.2	126
47	Primary renal non-Hodgkin's lymphoma. An unusual extranodal site. <i>Cancer</i> , 1995, 75, 2258-2261.	2.0	121
48	Yttrium 90-labeled Ibritumomab Tiuxetan Radioimmunotherapy Produces High Response Rates and Durable Remissions in Patients with Previously Treated B-Cell Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 98-101.	2.1	117
49	Soluble IL-2 receptor facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2011, 118, 2809-2820.	0.6	116
50	Consensus review of the clinical utility of dna flow cytometry in colorectal cancer. <i>Cytometry</i> , 1993, 14, 486-491.	1.8	111
51	Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 1492-1498.	0.6	110
52	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	3.4	110
53	Targeting NF- κ B in Waldenstrom macroglobulinemia. <i>Blood</i> , 2008, 111, 5068-5077.	0.6	106
54	Subsequent Chemotherapy Regimens Are Well Tolerated After Radioimmunotherapy With Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2002, 20, 3885-3890.	0.8	105

#	ARTICLE	IF	CITATIONS
55	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471.	2.6	96
56	Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. <i>Cancer</i> , 1994, 74, 2956-2963.	2.0	93
57	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	0.8	93
58	The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. <i>Blood</i> , 2015, 126, 328-335.	0.6	92
59	Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. <i>Blood</i> , 2012, 119, 476-487.	0.6	91
60	Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma. <i>British Journal of Haematology</i> , 1994, 87, 266-272.	1.2	89
61	The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. <i>Cancer</i> , 2010, 116, 2201-2207.	2.0	89
62	Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors. <i>Cancer</i> , 1993, 72, 1247-1260.	2.0	87
63	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. <i>Future Oncology</i> , 2016, 12, 1553-1563.	1.1	85
64	Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 629-636.	0.6	83
65	Prospective Randomized Trial of Melphalan and Prednisone Versus Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Primary Systemic Amyloidosis. <i>Journal of Clinical Oncology</i> , 1999, 17, 262-262.	0.8	77
66	Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma. <i>American Journal of Hematology</i> , 2016, 91, 571-574.	2.0	75
67	Osseous Hodgkin disease. , 1999, 85, 1166-1178.		72
68	Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. <i>Blood</i> , 2011, 118, 5540-5549.	0.6	72
69	Quantitation of circulating peripheral blood plasma cells and their relationship to disease activity in patients with multiple myeloma. <i>Cancer</i> , 1993, 72, 108-113.	2.0	71
70	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <i>Annals of Hematology</i> , 2018, 97, 1417-1425.	0.8	71
71	Multiple myeloma and the translocation t(11;14)(q13;q32): a report on 13 cases. <i>British Journal of Haematology</i> , 1998, 101, 296-301.	1.2	70
72	Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1620-1626.	0.8	70

#	ARTICLE	IF	CITATIONS
73	Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. <i>American Journal of Hematology</i> , 2014, 89, 237-242.	2.0	68
74	Plasmablastic Morphology Is an Independent Predictor of Poor Survival After Autologous Stem-Cell Transplantation for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 1999, 17, 1551-1551.	0.8	64
75	Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma. <i>Journal of Clinical Investigation</i> , 2019, 129, 1612-1625.	3.9	64
76	Syndecan-1 Expression on Malignant Cells from the Blood and Marrow of Patients with Plasma Cell Proliferative Disorders and B-Cell Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 1998, 31, 167-175.	0.6	62
77	Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2001, 68, 269-275.	2.0	61
78	Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412. <i>Journal of Clinical Oncology</i> , 2021, 39, 1329-1338.	0.8	60
79	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , 2015, 6, 5751.	5.8	58
80	Detection of myeloma cells in the peripheral blood by flow cytometry. , 1996, 26, 113-120.		57
81	Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial. <i>American Journal of Hematology</i> , 2011, 86, 640-645.	2.0	57
82	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1753-1754i.	0.9	57
83	<i>MYD88</i> mutation status does not impact overall survival in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 187-194.	2.0	57
84	Methemoglobinemia and hemolysis in a patient with G6PD deficiency treated with rasburicase. <i>American Journal of Hematology</i> , 2013, 88, 152-154.	2.0	56
85	Diagnosis of B-cell non-hodgkin's lymphoma of the central nervous system by immunocytochemical analysis of cerebrospinal fluid lymphocytes. <i>Cancer</i> , 1986, 57, 737-744.	2.0	55
86	Serum-free light chain—a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Translational Research</i> , 2007, 149, 231-235.	2.2	53
87	Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. <i>Blood</i> , 2012, 120, 4400-4406.	0.6	53
88	Inferior survival in high-grade B-cell lymphoma with <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements is not associated with <i>MYC/IG</i> gene rearrangements. <i>Haematologica</i> , 2018, 103, 1899-1907.	1.7	52
89	Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: A clinic-based case-control study. <i>Cytokine</i> , 2012, 60, 882-889.	1.4	50
90	Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085) Tj ETQq0 0 0 rgBT /Overlock 10 e309-e316.	2.2	50

#	ARTICLE	IF	CITATIONS
91	Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1947-1953.	2.4	50
92	Waldenström macroglobulinemia. <i>Current Treatment Options in Oncology</i> , 2004, 5, 239-247.	1.3	49
93	Is persistent polyclonal b lymphocytosis caused by epstein-barr virus? A study with polymerase chain reaction and in situ hybridization. <i>American Journal of Hematology</i> , 1992, 41, 270-275.	2.0	48
94	Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. <i>Blood</i> , 2015, 125, 992-998.	0.6	47
95	A proliferation-inducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation. <i>Blood</i> , 2009, 113, 5206-5216.	0.6	46
96	Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014, 55, 2728-2738.	0.6	44
97	Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 1819-1827.	0.8	44
98	RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. <i>Nature Communications</i> , 2021, 12, 2901.	5.8	44
99	Signal Transduction Inhibitor Therapy for Lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 265-270.	0.9	42
100	The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. <i>British Journal of Haematology</i> , 2011, 154, 477-481.	1.2	42
101	Definition of bulky disease in early stage Hodgkin lymphoma in computed tomography era: prognostic significance of measurements in the coronal and transverse planes. <i>Haematologica</i> , 2016, 101, 1237-1243.	1.7	42
102	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2019, 60, 2712-2719.	0.6	42
103	Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. <i>Oncotarget</i> , 2015, 6, 9488-9501.	0.8	42
104	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	2.0	41
105	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020, 188, 394-403.	1.2	41
106	Establishment and characterization of a novel Waldenström macroglobulinemia cell line, MWCL-1. <i>Blood</i> , 2011, 117, e190-e197.	0.6	40
107	The Effect of a Neutropenic Diet on Infection and Mortality Rates in Cancer Patients: A Meta-Analysis. <i>Nutrition and Cancer</i> , 2015, 67, 1232-1240.	0.9	40
108	Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018. <i>American Journal of Hematology</i> , 2019, 94, 291-298.	2.0	40

#	ARTICLE	IF	CITATIONS
109	Heterogeneity and Clinical Relevance of the Intensity of CD20 and Immunoglobulin Light-Chain Expression in B-Cell Chronic Lymphocytic Leukemia. <i>American Journal of Clinical Pathology</i> , 1996, 106, 457-461.	0.4	39
110	Effect of sonication on paraffin-embedded tissue preparation for DNA flow cytometry. <i>Cytometry</i> , 1990, 11, 642-646.	1.8	38
111	Hematologist/oncologist disease-specific expertise and survival: Lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). <i>Cancer</i> , 2012, 118, 1827-1837.	2.0	38
112	Efficacy and safety of 90Y ibritumomab tiuxetan (zevalin) radioimmunotherapy for non-Hodgkin's lymphoma. <i>Seminars in Oncology</i> , 2003, 30, 11-16.	0.8	37
113	Antilymphoma Treatments Given Subsequent to Yttrium 90 Ibritumomab Tiuxetan Are Feasible in Patients with Progressive Non-Hodgkin's Lymphoma: A Review of the Literature. <i>Clinical Lymphoma and Myeloma</i> , 2004, 5, 202-204.	2.1	37
114	Elevated pretreatment serum levels of interferon-inducible protein 10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. <i>American Journal of Hematology</i> , 2012, 87, 865-869.	2.0	37
115	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 73.	2.8	37
116	Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma. <i>Blood</i> , 2019, 134, 363-373.	0.6	37
117	Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011, 2, 95-113.	0.4	37
118	Radioimmunotherapy for B-cell non-Hodgkin lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2006, 19, 655-668.	0.7	36
119	Elevated soluble IL-2, IL-8, and MIP-1 β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma. <i>American Journal of Hematology</i> , 2014, 89, E223-7.	2.0	36
120	Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2018, 8, 97.	2.8	36
121	Longer-term follow-up and outcome by tumour cell proliferation rate (Ki67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL001(EMERGE) pivotal trial. <i>British Journal of Haematology</i> , 2015, 170, 496-503.	1.2	34
122	Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. <i>Leukemia and Lymphoma</i> , 2011, 52, 1188-1199.	0.6	33
123	A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and ⁹⁰ yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 589-593.	2.0	33
124	Impact of MYD88 ^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	2.0	33
125	Yttrium-90-ibritumomab tiuxetan radioimmunotherapy: A new treatment approach for B-cell non-Hodgkin's lymphoma. <i>Drugs of Today</i> , 2004, 40, 111.	2.4	32
126	Clinical Significance of the Translocation (11;14)(q13;q32) in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1999, 35, 599-605.	0.6	31

#	ARTICLE	IF	CITATIONS
127	Heavy chain disease. <i>Current Treatment Options in Oncology</i> , 2002, 3, 247-254.	1.3	31
128	A Review of Pathophysiology, Clinical Features, and Management Options of COVID-19 Associated Coagulopathy. <i>Shock</i> , 2021, 55, 700-716.	1.0	31
129	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed Aggressive Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2007, 110, 121-121.	0.6	31
130	Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?. <i>British Journal of Haematology</i> , 1995, 90, 459-461.	1.2	30
131	Unusual presentation of extranodal peripheral T-cell lymphomas with multiple paraneoplastic features. <i>Cancer</i> , 1991, 68, 834-841.	2.0	29
132	A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 467-467.	0.6	29
133	Thrombosis Related to the Use of L-Asparaginase in Adults with Acute Lymphoblastic Leukemia: a Need to Consider Coagulation Monitoring and Clotting Factor Replacement. <i>Leukemia and Lymphoma</i> , 1999, 32, 489-496.	0.6	28
134	Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2011, 86, 998-1000.	2.0	28
135	Primary systemic amyloidosis in patients with Waldenström macroglobulinemia. <i>Leukemia</i> , 2019, 33, 790-794.	3.3	28
136	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , 2021, 35, 522-533.	3.3	28
137	Radioimmunotherapy with Yttrium-90 Ibritumomab tiuxetan for patients with relapsed cd20+ B-Cell non-Hodgkin's Lymphoma. <i>Current Treatment Options in Oncology</i> , 2002, 3, 275-282.	1.3	27
138	Follow-Up Results of a Phase II Study of Ibritumomab Tiuxetan Radioimmunotherapy in Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma and Mild Thrombocytopenia. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004, 19, 478-481.	0.7	27
139	Acute coronary syndromes in patients with active hematologic malignancies " Incidence, management, and outcomes. <i>International Journal of Cardiology</i> , 2019, 275, 6-12.	0.8	27
140	Lack of intrafollicular memory CD4+T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 130.	2.8	27
141	Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. <i>American Journal of Hematology</i> , 2012, 87, 277-283.	2.0	26
142	Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 448-453.	2.0	26
143	History of autoimmune conditions and lymphoma prognosis. <i>Blood Cancer Journal</i> , 2018, 8, 73.	2.8	26
144	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. <i>Blood</i> , 2019, 134, 1289-1297.	0.6	26

#	ARTICLE	IF	CITATIONS
145	Cardiac Outcomes in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. <i>Blood</i> , 2011, 118, 2656-2656.	0.6	26
146	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenström macroglobulinemia. <i>British Journal of Haematology</i> , 2017, 179, 98-105.	1.2	25
147	Proliferative Activity in Non-Hodgkin's Lymphomas: A Comparison of the Bromodeoxyuridine Labeling Index with PCNA Immunostaining and Quantitative Image Analysis. <i>American Journal of Clinical Pathology</i> , 1993, 99, 668-672.	0.4	24
148	Drugs with anti-oxidant properties can interfere with cell viability measurements by assays that rely on the reducing property of viable cells. <i>Laboratory Investigation</i> , 2017, 97, 494-497.	1.7	24
149	Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2018, 93, 1384-1393.	2.0	24
150	Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 48.	2.8	24
151	Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 752-758.	2.0	23
152	T-cell chronic lymphocytic leukemia with a helper/inducer membrane phenotype: A distinct clinicopathologic subtype with a poor prognosis. <i>American Journal of Hematology</i> , 1986, 21, 139-155.	2.0	22
153	Treatment of Refractory T-Cell Chronic Lymphocytic Leukemia with Purine Nucleoside Analogues. <i>Leukemia and Lymphoma</i> , 1994, 14, 137-139.	0.6	22
154	A Two-Stage Evaluation of Genetic Variation in Immune and Inflammation Genes with Risk of Non-Hodgkin Lymphoma Identifies New Susceptibility Locus in 6p21.3 Region. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1799-1806.	1.1	22
155	Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma. <i>Blood Cancer Journal</i> , 2018, 8, 110.	2.8	22
156	CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. <i>Blood Cancer Journal</i> , 2018, 8, 63.	2.8	22
157	A Novel Missense (M206K) STAT3 Mutation in Diffuse Large B Cell Lymphoma Deregulates STAT3 Signaling. <i>PLoS ONE</i> , 2013, 8, e67851.	1.1	20
158	CSF1R Inhibition by PLX3397 in Patients with Relapsed or Refractory Hodgkin Lymphoma: Results From a Phase 2 Single Agent Clinical Trial. <i>Blood</i> , 2012, 120, 1638-1638.	0.6	20
159	Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy. <i>Cancer</i> , 2006, 107, 433-438.	2.0	19
160	A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I-II) diffuse large B-cell non-Hodgkin lymphoma: ECOG 3402. <i>British Journal of Haematology</i> , 2015, 170, 679-686.	1.2	19
161	Acalabrutinib for mantle cell lymphoma. <i>Blood</i> , 2019, 133, 2570-2574.	0.6	19
162	Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein 10 predicts inferior prognosis in untreated diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 417-422.	2.0	18

#	ARTICLE	IF	CITATIONS
163	Magnesium: The overlooked electrolyte in blood cancers?. <i>Blood Reviews</i> , 2020, 44, 100676.	2.8	18
164	Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2019, 134, 751-751.	0.6	18
165	A Phase 2/3 Multicenter, Randomized Study Comparing the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Relapsed/Refractory DLBCL. <i>Blood</i> , 2014, 124, 628-628.	0.6	18
166	Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. <i>American Journal of Hematology</i> , 2017, 92, E575-E583.	2.0	17
167	Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. <i>Haematologica</i> , 2018, 103, 297-303.	1.7	17
168	PD-1 Blockade with Pembrolizumab (MK-3475) in Relapsed/Refractory CLL Including Richter Transformation: An Early Efficacy Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2015, 126, 834-834.	0.6	17
169	Non-Hodgkin Lymphoma B-Cells Induce Intratumoral CD4+CD25 ^{hi} T Cells To Express Foxp3 and Gain Regulatory Function.. <i>Blood</i> , 2006, 108, 1724-1724.	0.6	17
170	Treatment of late-stage Sezary syndrome with 2-Chlorodeoxyadenosine. <i>International Journal of Dermatology</i> , 2002, 41, 352-356.	0.5	16
171	Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B-cell and T-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 1116-1120.	2.0	16
172	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , 2018, 93, 1543-1550.	2.0	16
173	Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells. <i>British Journal of Haematology</i> , 2018, 183, 196-211.	1.2	16
174	A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408. <i>Clinical Cancer Research</i> , 2020, 26, 4468-4477.	3.2	16
175	Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. <i>Journal of Clinical Oncology</i> , 2021, 39, 1641-1649.	0.8	16
176	Efficacy of Splenectomy for Patients with Mantle Cell Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2001, 42, 1235-1241.	0.6	16
177	Combination Therapy with CC-5013 (Lenalidomide; Revlimid,®) Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma (MM).. <i>Blood</i> , 2004, 104, 331-331.	0.6	16
178	A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LRCD) for untreated low-grade non-Hodgkin lymphoma requiring therapy. <i>American Journal of Hematology</i> , 2017, 92, 467-472.	2.0	15
179	Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 427-433.	1.2	15
180	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	1.1	15

#	ARTICLE	IF	CITATIONS
181	Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 786-793.	2.0	15
182	Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 995-1002.	2.5	15
183	Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. <i>Oncologist</i> , 2020, 25, 974-980.	1.9	15
184	Dysregulation of GPR34 in Indolent Lymphomas and Its Function As a Novel Regulator of Cell Growth and Gene Expression. <i>Blood</i> , 2011, 118, 1570-1570.	0.6	15
185	Detection of monoclonal plasma cells in the peripheral blood of patients with primary amyloidosis. <i>British Journal of Haematology</i> , 1998, 100, 326-327.	1.2	14
186	Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial. <i>Lancet Haematology</i> , 2020, 7, e490-e497.	2.2	14
187	Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma. <i>Blood Advances</i> , 2021, 5, 1194-1198.	2.5	14
188	mTOR Inhibition for Relapsed or Refractory Hodgkin Lymphoma: Promising Single Agent Activity with Everolimus (RAD001).. <i>Blood</i> , 2007, 110, 2555-2555.	0.6	14
189	Rapid S-Phase Determination of Non-Hodgkin's Lymphomas with the Use of an Immunofluorescence Bromodeoxyuridine Labeling Index Procedure. <i>American Journal of Clinical Pathology</i> , 1989, 91, 298-301.	0.4	13
190	Asthma and orbital immunoglobulin G4-related disease. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 116, 313-316.	0.5	13
191	A Pilot Study of Pomalidomide and Dexamethasone in Previously Treated Light Chain Amyloidosis Patients.. <i>Blood</i> , 2009, 114, 3854-3854.	0.6	13
192	Elevated serum LDH in patients with non-Hodgkin's lymphoma: not always an ominous sign. <i>British Journal of Haematology</i> , 1999, 107, 463-464.	1.2	12
193	Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 820-828.	1.2	12
194	Increased glutathione utilization augments tumor cell proliferation in Waldenstrom Macroglobulinemia. <i>Redox Biology</i> , 2020, 36, 101657.	3.9	12
195	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2021, 96, 945-953.	2.0	12
196	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , 2021, 195, 210-216.	1.2	12
197	Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 699-704.	0.2	11
198	Pseudo-monoclonal gammopathy: a report of four cases. <i>Haematologica</i> , 2017, 102, e466-e469.	1.7	11

#	ARTICLE	IF	CITATIONS
199	Variable global distribution of cell-of-origin from the ROBUST phase III study in diffuse large B-cell lymphoma. <i>Haematologica</i> , 2020, 105, e72-e75.	1.7	11
200	Early Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma. <i>Blood</i> , 2006, 108, 2482-2482.	0.6	11
201	Clinical Activity of Single Dose Systemic Oncolytic VSV Virotherapy in Patients with Relapsed Refractory T-Cell Lymphoma. <i>Blood Advances</i> , 2022, , .	2.5	11
202	Accuracy of 18-F FDG PET/CT to detect bone marrow clearance in patients with peripheral T-cell lymphoma – tissue remains the issue. <i>Leukemia and Lymphoma</i> , 2017, 58, 2342-2348.	0.6	10
203	Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. <i>Blood Cancer Journal</i> , 2018, 8, 27.	2.8	10
204	Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate. <i>Supportive Care in Cancer</i> , 2021, 29, 5293-5301.	1.0	10
205	Elevated Serum Lactate in Patients With Lymphoma: It Is Not Always Infection. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 423-430.	1.2	10
206	Expression of Interferon Regulatory Factor-4 (IRF4/MUM1) Is Associated with Inferior Overall Survival In Peripheral T-Cell Lymphoma. <i>Blood</i> , 2010, 116, 140-140.	0.6	10
207	The utility of restaging bone marrow biopsy in PET-negative patients with diffuse large B-cell lymphoma and baseline bone marrow involvement. <i>American Journal of Hematology</i> , 2014, 89, 865-867.	2.0	9
208	Work-Life Balance Solutions for Physicians – It's All About You, Your Work, and Others. <i>Mayo Clinic Proceedings</i> , 2019, 94, 573-576.	1.4	9
209	Persistent mediastinal FDG uptake on PET-CT after frontline therapy for Hodgkin lymphoma: biopsy, treat or observe?. <i>Leukemia and Lymphoma</i> , 2020, 61, 318-327.	0.6	9
210	Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. <i>American Journal of Hematology</i> , 2020, 95, E57-E60.	2.0	9
211	Salicylates enhance CRM1 inhibitor antitumor activity by induction of S-phase arrest and impairment of DNA-damage repair. <i>Blood</i> , 2021, 137, 513-523.	0.6	9
212	Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 8.	2.8	9
213	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. <i>Blood Advances</i> , 2022, 6, 1350-1360.	2.5	9
214	Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease. <i>American Journal of Hematology</i> , 2022, 97, 293-302.	2.0	9
215	Serial Studies of Peripheral Blood Myeloma Cells in Patients with Multiple Myeloma: When is the Optimal Time for Stem Cell Harvest?. <i>Leukemia and Lymphoma</i> , 1995, 19, 417-422.	0.6	8
216	Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors. <i>Leukemia and Lymphoma</i> , 2021, 62, 247-251.	0.6	8

#	ARTICLE	IF	CITATIONS
217	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type. <i>Hematological Oncology</i> , 2021, 39, 658-663.	0.8	8
218	Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. <i>Blood</i> , 2019, 134, 468-468.	0.6	8
219	Intravascular Lymphoma: Poor Outcomes May Be Improved with Aggressive Therapy.. <i>Blood</i> , 2005, 106, 938-938.	0.6	8
220	Combination of Lenalidomide with R-CHOP (R2CHOP) Is Well-Tolerated and Effective As Initial Therapy for Aggressive B-Cell Lymphomas - A Phase II Study. <i>Blood</i> , 2012, 120, 689-689.	0.6	8
221	Randomized Phase 2 Trial of Two Different Doses of Ixazomib in Patients with Relapsed Multiple Myeloma Not Refractory to Bortezomib. <i>Blood</i> , 2015, 126, 3050-3050.	0.6	8
222	PD-1 Blockade with Pembrolizumab in Relapsed CLL Including Richter's Transformation: An Updated Report from a Phase 2 Trial (MC1485). <i>Blood</i> , 2016, 128, 4392-4392.	0.6	8
223	Rituximab-based maintenance therapy in Waldenström macroglobulinemia: A case control study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7559-7559.	0.8	8
224	Waldenström Macroglobulinemia in the Very Elderly (≥75 years):Clinical Characteristics and Outcomes. <i>Blood</i> , 2020, 136, 44-45.	0.6	8
225	Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab. <i>Mayo Clinic Proceedings</i> , 2007, 82, 692-9.	1.4	8
226	S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma. <i>Cancer</i> , 1995, 76, 1059-1064.	2.0	7
227	Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC). <i>American Journal of Hematology</i> , 2017, 92, 1004-1010.	2.0	7
228	The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells. <i>Blood Cancer Journal</i> , 2019, 9, 24.	2.8	7
229	Primary Cutaneous Acral CD8+ T-Cell Lymphoma—A Single Center Review of 3 Cases and Recent Literature Review. <i>American Journal of Dermatopathology</i> , 2019, 41, 644-648.	0.3	7
230	Fluorodeoxyglucose-Positron Emission Tomography Predicts Bone Marrow Involvement in the Staging of Follicular Lymphoma. <i>Oncologist</i> , 2020, 25, 689-695.	1.9	7
231	Prospective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function. <i>Clinical and Translational Science</i> , 2022, 15, 105-117.	1.5	7
232	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. <i>Blood</i> , 2019, 134, 121-121.	0.6	7
233	Role of B-Lymphocyte Stimulator (BLyS) in Waldenström's Macroglobulinemia.. <i>Blood</i> , 2005, 106, 601-601.	0.6	7
234	A Phase I/II Trial of Lenalidomide and RCHOP (R2CHOP) in Patients with Newly Diagnosed Diffuse Large B-Cell (DLBCL) and Follicular Grade 3 Lymphoma.. <i>Blood</i> , 2009, 114, 1669-1669.	0.6	7

#	ARTICLE	IF	CITATIONS
235	Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003).. Blood, 2009, 114, 1676-1676.	0.6	7
236	Flow Cytometric Detection of Circulating Myeloma Cells Pretransplant in Patients with Multiple Myeloma: A Simple Risk Stratification System.. Blood, 2005, 106, 1164-1164.	0.6	7
237	Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. Blood Cancer Journal, 2022, 12, 1.	2.8	7
238	A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 664-672.e2.	0.2	6
239	Anti-Tumor Activity of Single-Agent CCI-779 for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group.. Blood, 2004, 104, 129-129.	0.6	6
240	Incidence and Clinical Course of Peripheral Neuropathy in Patients Receiving Thalidomide for the Treatment of Multiple Myeloma.. Blood, 2005, 106, 3475-3475.	0.6	6
241	Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SP0RE (CA97274).. Blood, 2006, 108, 530-530.	0.6	6
242	A Phase II Study of Temsirolimus (CCI-779) in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma.. Blood, 2009, 114, 1665-1665.	0.6	6
243	A Novel Long Non-Coding RNA, SNHG4 Complex With Eukaryotic Initiation Factor-4E and Regulate Aberrant Protein Translation In Mantle Cell Lymphoma: Implications For Novel Biomarker. Blood, 2013, 122, 81-81.	0.6	6
244	Treatment Patterns and Outcomes of DLBCL after Failure of Front-Line Immunochemotherapy. Blood, 2015, 126, 2683-2683.	0.6	6
245	Absolute Lymphocyte Count and CD4 Count Predict a Superior Progression-Free Survival in Non-Hodgkin Lymphoma Patients Treated with Rituximab and Interleukin-12.. Blood, 2005, 106, 1495-1495.	0.6	6
246	Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The <sc>FUSION NHL</sc> 001 trial. Cancer Reports, 2023, 6, .	0.6	6
247	A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma. Leukemia and Lymphoma, 2018, 59, 2128-2134.	0.6	5
248	Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. British Journal of Haematology, 2018, 183, 149-152.	1.2	5
249	Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. American Journal of Hematology, 2021, 96, 979-988.	2.0	5
250	Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies. JCO Oncology Practice, 2021, 17, e1382-e1393.	1.4	5
251	Combination Therapy with Lenalidomide Plus Dexamethasone (Rev/Dex) for Newly Diagnosed Myeloma.. Blood, 2005, 106, 781-781.	0.6	5
252	Absolute Lymphocyte Count Recovery Predicts Superior Survival and Is Independent of the International Prognostic Index in Patients Treated with CHOP or R-CHOP Chemotherapy for Diffuse Large B Cell Lymphoma.. Blood, 2005, 106, 931-931.	0.6	5

#	ARTICLE	IF	CITATIONS
253	A Phase II Study of the Farnesyltransferase Inhibitor Tipifarnib Demonstrates Anti-Tumor Activity In Patients with Relapsed and Refractory Lymphomas. <i>Blood</i> , 2010, 116, 287-287.	0.6	5
254	Primary Pulmonary MALT Lymphoma: Clinical Characteristics and Treatment Outcomes â€” Single Institution Experience. <i>Blood</i> , 2010, 116, 4168-4168.	0.6	5
255	Repression Of Cap-Dependent Translation With a Next-Generation mTOR Inhibitor Attenuates c-Myc Transcription and Survival In Lymphoma Cells. <i>Blood</i> , 2013, 122, 636-636.	0.6	5
256	In-Vivo Activation Of STAT3 In Angioimmunoblastic T Cell Lymphoma, PTCL Not Otherwise Specified, and ALK Negative Anaplastic Large Cell Lymphoma: Implications For Therapy. <i>Blood</i> , 2013, 122, 844-844.	0.6	5
257	Drug Resistance Alters CD38 Expression and in Vitro Response to Daratumumab in Waldenstrom Macroglobulinemia Cells. <i>Blood</i> , 2016, 128, 3018-3018.	0.6	5
258	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , 2016, 128, 3034-3034.	0.6	5
259	Lenalidomide Combined with R-CHOP (R2CHOP) Overcomes Negative Prognostic Impact of ABC Molecular Subtype in Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 3035-3035.	0.6	5
260	Low Plasma Omega-3 Fatty Acid Levels May Predict Inferior Prognosis in Untreated Diffuse Large B-Cell Lymphoma: A New Modifiable Dietary Biomarker?. <i>Nutrition and Cancer</i> , 2018, 70, 1088-1090.	0.9	4
261	Hypomagnesemia is associated with an increased risk of early clinical failure in patients with Burkitt lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2274-2276.	0.6	4
262	Outcomes in mantle cell lymphoma with central nervous system involvement.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19527-e19527.	0.8	4
263	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. <i>Blood Cancer Journal</i> , 2021, 11, 133.	2.8	4
264	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. <i>Blood</i> , 2019, 134, 4092-4092.	0.6	4
265	Long-Term Outcome of Patients with Low-Grade Follicular Lymphoma Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience. <i>Blood</i> , 2019, 134, 2809-2809.	0.6	4
266	Bendamustine and Rituximab Versus Dexamethasone, Rituximab and Cyclophosphamide in Patients with Waldenstrom Macroglobulinemia (WM). <i>Blood</i> , 2016, 128, 2968-2968.	0.6	4
267	Molecular Mechanisms Involved in Homing and Migration of B-Chronic Lymphocytic Leukemia (CLL) in Response to CXCR4 Stimulation and Downstream Activation of the PI3K Pathway.. <i>Blood</i> , 2004, 104, 1909-1909.	0.6	4
268	Expression of VEGF Receptors on Plasma Cells: Evidence of Heterogeneity.. <i>Blood</i> , 2004, 104, 3361-3361.	0.6	4
269	Histone Deacetylase Inhibition with LBH589 Inhibits the Rapamycin Insensitive Rictor-mTOR (mTORC2) Complex and Translation Initiation Factor eIF4E Activation in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2008, 112, 603-603.	0.6	4
270	Germline Variation in Complement Genes and Event-Free Survival in Follicular Lymphoma.. <i>Blood</i> , 2009, 114, 440-440.	0.6	4

#	ARTICLE	IF	CITATIONS
271	V LX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia. <i>Blood</i> , 2015, 126, 703-703.	0.6	4
272	Real World Long-term Follow-up Experience with Yttrium-90Âbritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 618-625.	0.2	4
273	Clinical Characteristics, Prognostic Indicators, and Survival Outcomes in Intravascular Lymphoma: Mayo Clinic Experience (2003â€“2018). <i>American Journal of Hematology</i> , 0, , .	2.0	4
274	Measurement of the Cell Proliferation Rate of Bone Marrow Erythroid Precursors by Flow Cytometry: Initial Applications to Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1998, 30, 353-359.	0.6	3
275	Moving Radioimmunotherapy Forward for Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 294-296.	0.8	3
276	Epstein-Barr Virus Infection in an Elderly Nonimmunocompromised Adult Successfully Treated with Rituximab. <i>Case Reports in Hematology</i> , 2014, 2014, 1-4.	0.3	3
277	Origins research in large cell lymphomaâ€”time for action?. <i>Lancet Oncology</i> , The, 2014, 15, 674-675.	5.1	3
278	Response to: â€”Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4â€”yearsâ€” by Yamamoto et al. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e47-e47.	0.5	3
279	Testicular ^{FDG}PET</sup>/^{CT} uptake threshold in aggressive lymphomas. <i>American Journal of Hematology</i> , 2021, 96, E81-E83.	2.0	3
280	Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 308-315.	0.6	3
281	Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure. <i>Blood Cancer Journal</i> , 2021, 11, 65.	2.8	3
282	JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis. <i>Blood Cancer Journal</i> , 2021, 11, 56.	2.8	3
283	Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia. <i>Scientific Reports</i> , 2021, 11, 8318.	1.6	3
284	Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7522-7522.	0.8	3
285	Clinical activity of systemic VSV-IFNÎ²-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2500-2500.	0.8	3
286	Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. <i>Blood Cancer Journal</i> , 2021, 11, 160.	2.8	3
287	Protocol Modification To Determine The Cytotoxic Potential Of Drugs Using Cell Viability Assays That Rely On The Reducing Property Of Viable Cells. <i>Protocol Exchange</i> , 0, , .	0.3	3
288	A Randomized Phase 2 Study Comparing Acabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2019, 134, 4306-4306.	0.6	3

#	ARTICLE	IF	CITATIONS
289	Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database. <i>Blood</i> , 2019, 134, 1610-1610.	0.6	3
290	R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. <i>Blood</i> , 2020, 136, 39-40.	0.6	3
291	Rapamycin Enhances the Cytotoxicity of Bortezomib and Rituximab on Mantle Cell Lymphoma (MCL) Cell Lines.. <i>Blood</i> , 2005, 106, 2411-2411.	0.6	3
292	Elevated Expression of GPR34 and Its Association with a Novel Translocation T(X;14)(p11;q32) Involving IGHS and GPR34 in MALT Lymphoma.. <i>Blood</i> , 2008, 112, 2251-2251.	0.6	3
293	Clarithromycin (Biaxin)-Lenalidomide-Low-Dose Dexamethasone (BiRd) Versus Lenalidomide-Low-Dose Dexamethasone (Rd) as Initial Therapy for Newly Diagnosed Multiple Myeloma.. <i>Blood</i> , 2009, 114, 2868-2868.	0.6	3
294	Expression of Cytoplasmic and Surface VEGF by Plasma Cells in Myeloma and Related Disorders.. <i>Blood</i> , 2004, 104, 3655-3655.	0.6	3
295	Barriers to Enrollment in Clinical Trials in Patients with Aggressive B-Cell Non-Hodgkin Lymphoma That Progressed after Anti-CD19 CART Cell Therapy. <i>Blood</i> , 2021, 138, 2527-2527.	0.6	3
296	Myc matters in HIV-associated lymphoma. <i>Blood</i> , 2020, 136, 1217-1218.	0.6	2
297	Bone involvement on PET/CT predicts event-free survival in follicular lymphoma Grade 3B. <i>British Journal of Haematology</i> , 2020, 191, e41-e43.	1.2	2
298	Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19547-e19547.	0.8	2
299	Ibritumomab Tiuxetan Radioimmunotherapy for Primary Gastrointestinal Follicular Lymphoma. <i>Oncologist</i> , 2021, 26, e2079-e2081.	1.9	2
300	Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study. <i>Blood</i> , 2018, 132, 2937-2937.	0.6	2
301	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. <i>Blood</i> , 2020, 136, 7-8.	0.6	2
302	The Green Tea Extract Epigallocatechin Induces In Vitro Cell Death in Primary Human Lymphoma Cells through an ROS Dependent Mechanism.. <i>Blood</i> , 2006, 108, 234-234.	0.6	2
303	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. <i>Blood</i> , 2007, 110, 4496-4496.	0.6	2
304	Phase 1 Trial of Sorafenib and Everolimus In Patients with Lymphoma or Multiple Myeloma.. <i>Blood</i> , 2010, 116, 2802-2802.	0.6	2
305	Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010, 116, 996-996.	0.6	2
306	Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population. <i>Blood</i> , 2012, 120, 1540-1540.	0.6	2

#	ARTICLE	IF	CITATIONS
307	Outcomes and Treatments of Relapsed AL Amyloidosis Following Stem Cell Transplant. Blood, 2012, 120, 1858-1858.	0.6	2
308	A Phase II Trial of R-CHOP Followed by Zevalin Radioimmunotherapy for Patients with Previously Untreated Stages I and II CD20+ Diffuse Large Cell Non-Hodgkin's Lymphoma: an Eastern Cooperative Oncology Group Study (E3402).. Blood, 2012, 120, 2687-2687.	0.6	2
309	Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results. Blood, 2012, 120, 3680-3680.	0.6	2
310	Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib. Blood, 2013, 122, 3057-3057.	0.6	2
311	IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. Blood, 2013, 122, 362-362.	0.6	2
312	Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma. Blood, 2015, 126, 1557-1557.	0.6	2
313	Prognostic Impact of Morphology, MYC Gene Partner and BCL2/BCL6 Translocation Status in "High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements". Blood, 2016, 128, 1750-1750.	0.6	2
314	Dexamethasone, Rituximab and Cyclophosphamide (DRC) As Salvage Therapy for Waldenstrom Macroglobulinemia. Blood, 2016, 128, 2972-2972.	0.6	2
315	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with DLBCL Is Associated with a Lower Risk of CNS Relapse: Combined Analysis from Two Phase 2 Studies. Blood, 2016, 128, 3033-3033.	0.6	2
316	Feasibility of real-time cell-of-origin subtype identification by gene expression profile in the phase 3 trial of lenalidomide plus R-CHOP vs placebo plus R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma (ROBUST).. Journal of Clinical Oncology, 2016, 34, 7538-7538.	0.8	2
317	In Smoldering/Indolent (SMM/IMM) Myeloma Patients Treated with Interleukin-1 Receptor Antagonist (IL-1Ra), Responders Demonstrate a Significantly Increased Time to Progression (TTP) and a Decreased C-Reactive Protein (CRP) Compared with Nonresponders.. Blood, 2005, 106, 2567-2567.	0.6	2
318	Role of CCL5 and Interleukin-6 in the Biology of Waldenstrom Macroglobulinemia.. Blood, 2007, 110, 688-688.	0.6	2
319	A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).. Blood, 2007, 110, 124-124.	0.6	2
320	A Phase II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Relapsed or Refractory Waldenstrom's Macroglobulinemia.. Blood, 2009, 114, 587-587.	0.6	2
321	Depth of Response in Waldenstrom Macroglobulinemia. Blood, 2018, 132, 4141-4141.	0.6	2
322	Long-Term Outcome of Patients with Marginal Zone Non-Hodgkin Lymphoma (MZL) Treated with Yttrium-90 Ibritumomab Tiuxetan: The Mayo Clinic Experience. Blood, 2019, 134, 1544-1544.	0.6	2
323	Central Nervous System Involvement in Peripheral T-Cell Lymphoma. Blood, 2019, 134, 5293-5293.	0.6	2
324	What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and Outcomes?. Hematology/Oncology Clinics of North America, 2020, 34, 825-835.	0.9	2

#	ARTICLE	IF	CITATIONS
325	Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma. <i>Blood</i> , 2021, 138, 621-621.	0.6	2
326	Impact of Novel Agents on the Outcomes of Patients with Classic Hodgkin Lymphoma That Relapsed after Autologous Stem Cell Transplant. <i>Blood</i> , 2021, 138, 1373-1373.	0.6	2
327	Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2022, , .	2.0	2
328	Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e815-e825.	0.2	2
329	Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. <i>Blood Advances</i> , 2022, 6, 5210-5221.	2.5	2
330	Platelet transfusion therapy in acute leukemia: Lack of effect of splenomegaly on transfusion requirements and risk of hemorrhage. <i>American Journal of Hematology</i> , 1985, 18, 345-350.	2.0	1
331	A new tool in the cancer immunotherapy toolbox?. <i>Annals of Lymphoma</i> , 2018, 1, 1-1.	4.5	1
332	Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1117-e1122.	0.9	1
333	Host genetic variation in tumor necrosis factor and nuclear factor- κ B pathways and overall survival in mantle cell lymphoma: A discovery and replication study. <i>American Journal of Hematology</i> , 2019, 94, E153-E155.	2.0	1
334	Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8049-8049.	0.8	1
335	Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7542-7542.	0.8	1
336	Type of tissue biopsy and outcomes in diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , 2021, 39, e13569-e13569.	0.8	1
337	MCIR1: A patient-derived mantle cell lymphoma line for discovering new treatments for ibrutinib resistance. <i>European Journal of Haematology</i> , 2021, 107, 458-465.	1.1	1
338	Relapses after Achieving EFS24 in Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2018, 132, 454-454.	0.6	1
339	The Prognostic Impact of Baseline Positron Emission Tomography (PET) Imaging in Untreated High Risk (HR) Follicular Lymphoma (FL): Analysis from E2408, the Bortezomib Induction or Novel Imidazole Continuation (BIONIC) Study. <i>Blood</i> , 2018, 132, 1615-1615.	0.6	1
340	Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL. <i>Blood</i> , 2018, 132, 4204-4204.	0.6	1
341	Longitudinal Adverse Event Assessment of the Combination of Ipilimumab, Nivolumab and Brentuximab Vedotin in Relapsed / Refractory Hodgkin Lymphoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4412: Arms A-F). <i>Blood</i> , 2018, 132, 623-623.	0.6	1
342	High Efficacy of Lenalidomide Plus R-CHOP (R2CHOP) Combination in First Line Treatment of Activated B-Cell (ABC) DLBCL Defined Using Gene-Expression Profiling: A Combined Analysis from Two Phase 2 Trials. <i>Blood</i> , 2018, 132, 2962-2962.	0.6	1

#	ARTICLE	IF	CITATIONS
343	Maximizing FDG-PET/CT Utility in Staging of Follicular Lymphoma (FL): The Role of Spleen Involvement and Bone Standardized Uptake Values. <i>Blood</i> , 2019, 134, 2811-2811.	0.6	1
344	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2020, 136, 7-8.	0.6	1
345	Phase I Clinical Study of Atacicept in Patients with Relapsed and Refractory B-Cell Lymphoma.. <i>Blood</i> , 2006, 108, 2722-2722.	0.6	1
346	A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289). <i>Blood</i> , 2010, 116, 3053-3053.	0.6	1
347	OSI-027, a Dual TORC1/TORC2 Inhibitor, Induces Bim- and Puma-Mediated Apoptosis In Lymphoid Malignancy. <i>Blood</i> , 2010, 116, 970-970.	0.6	1
348	Primary Parotid MALT Lymphoma: Clinical Characteristics and Treatment â€“ a Single Institution Experience. <i>Blood</i> , 2011, 118, 1580-1580.	0.6	1
349	Prior Rituximab Exposure Does Not Appear to Affect Time to Treatment Failure After Radioimmunotherapy. <i>Blood</i> , 2011, 118, 1640-1640.	0.6	1
350	Pentostatin, Alemtuzumab, and Low Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL). <i>Blood</i> , 2011, 118, 1790-1790.	0.6	1
351	A Phase I Trial of Zevalin Radioimmunotherapy with High-Dose Melphalan (HDM) and Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM). <i>Blood</i> , 2011, 118, 3095-3095.	0.6	1
352	Phase I Trial of Rituximab, Cladribine and Temozolomide (RCT) for Initial Therapy of Mantle Cell Lymphoma. <i>Blood</i> , 2012, 120, 3661-3661.	0.6	1
353	Survival After Second, Third, and Fourth Line Therapy Better Than Expected in Patients with Previously Treated AL Amyloidosis Who Were Not Transplant Candidates At Diagnosis.. <i>Blood</i> , 2012, 120, 946-946.	0.6	1
354	Incidence and Outcomes of Treatment Refractory Diffuse Large B-Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015, 126, 3992-3992.	0.6	1
355	Everolimus Plus RCHOP-21 Is Safe and Highly Effective for New Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results of the Phase I Trial NCCTG1085 (Alliance). <i>Blood</i> , 2015, 126, 813-813.	0.6	1
356	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. <i>Blood</i> , 2016, 128, 1104-1104.	0.6	1
357	Treatment and Clinical Outcomes of High Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements (Double Hit/Triple Hit Lymphomas). <i>Blood</i> , 2016, 128, 155-155.	0.6	1
358	Waldenstrom Macroglobulinemia Cells Modulate Mitochondrial Bioenergetics and Induce a Respiratory Hyper-Drive State upon Acquisition of Ibrutinib-Resistance. <i>Blood</i> , 2016, 128, 2761-2761.	0.6	1
359	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. <i>Blood</i> , 2016, 128, 5299-5299.	0.6	1
360	Randomized, phase III trial of the efficacy and safety of lenalidomide plus R-CHOP vs R-CHOP in patients with untreated ABC-type diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS8600-TPS8600.	0.8	1

#	ARTICLE	IF	CITATIONS
361	Interleukin-1 Receptor Antagonist (IL-1Ra) Targets the Proliferative Component in Early Stage Myeloma.. Blood, 2004, 104, 2412-2412.	0.6	1
362	B-Lymphocyte Stimulator (BLyS) Is Highly Expressed in Waldenstrom's Macroglobulinemia.. Blood, 2004, 104, 2291-2291.	0.6	1
363	Phenotypic Characterization of the CD45+ and CD45 ^{hi} Plasma Cell Compartments in Monoclonal Gammopathies.. Blood, 2006, 108, 3505-3505.	0.6	1
364	APRIL-TACI Interactions Mediate Non-Hodgkin Lymphoma B Cell Proliferation through Akt Regulated Cyclin D1 and P21.. Blood, 2007, 110, 3585-3585.	0.6	1
365	Absolute Lymphocyte Count at the Time of Relapse Predicts Survival in Patients with Diffuse Large B-Cell Lymphoma.. Blood, 2008, 112, 1763-1763.	0.6	1
366	Interplay Between Histone Deacetylases (HDACs) and STAT3: Mechanism of Activated JAK/STAT3 Oncogenic Pathway in ABC (Activated B-cell) Type Diffuse Large B Cell Lymphoma.. Blood, 2009, 114, 925-925.	0.6	1
367	Germline Variation in Apoptosis Pathway Genes and Risk of Non-Hodgkin Lymphoma.. Blood, 2009, 114, 3933-3933.	0.6	1
368	Inhibition of the Jak/Stat Pathway Downregulates Immunoglobulin Production and Induces Cell Death in Waldenstrom's Macroglobulinemia.. Blood, 2009, 114, 1691-1691.	0.6	1
369	Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. Blood, 2010, 116, 991-991.	0.6	1
370	A Novel IL-12-TIM-3 Pathway Induces T Cell Exhaustion and Predicts Reduced Survival In Patients with Follicular B-Cell Non-Hodgkin Lymphoma. Blood, 2010, 116, 143-143.	0.6	1
371	Long Term Follow-up of IL-1 Receptor Antagonist and Dexamethasone Phase II Clinical Trial in Patients with Smoldering/Indolent Myeloma Shows Improved Survival in Responsive Patients: Implications for Targeting Interleukin-1 Induced IL-6 Production and the Myeloma Proliferative Component. Blood, 2011, 118, 2945-2945.	0.6	1
372	TGF- β 2 Is Selectively Expressed on Lymphoma B Cells and Regulates the Differentiation of Intratumoral T Cells in B-Cell Non-Hodgkin Lymphoma (NHL). Blood, 2011, 118, 1586-1586.	0.6	1
373	Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. Blood, 2011, 118, 429-429.	0.6	1
374	The Absolute Monocyte Count Predicts Overall Survival In Patients Newly Diagnosed with Follicular Lymphoma. Blood, 2011, 118, 85-85.	0.6	1
375	PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus in poor-risk diffuse large B-cell lymphoma (DLBCL).. Journal of Clinical Oncology, 2012, 30, TPS8118-TPS8118.	0.8	1
376	EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (âˆ-) Counterparts: Results From University of Iowa/Mayo Clinic SPORE. Blood, 2012, 120, 1604-1604.	0.6	1
377	A Novel STAT3 mutation Associated with Diffuse Large B Cell Lymphoma Deregulates STAT3 Signaling.. Blood, 2012, 120, 2690-2690.	0.6	1
378	SHP1 Suppression In Diffuse Large B Cell Lymphoma Is Regulated Through Promoter Hypermethylation At Novel CpG2 Island and H3K27 Trimethylation Histone Mark. Blood, 2013, 122, 632-632.	0.6	1

#	ARTICLE	IF	CITATIONS
379	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. <i>Blood</i> , 2013, 122, 76-76.	0.6	1
380	Novel Mutations in NOTCH and Altered Wnt/ β -Catenin Pathway Indicate a Role of Embryonic Signals in the Pathogenesis of T-Cell Prolymphocytic Leukemia. <i>Blood</i> , 2016, 128, 4103-4103.	0.6	1
381	Treatment Facility Volume and Outcomes in Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 622-622.	0.6	1
382	Clinical Significance of Testicular FDG-PET/CT Uptake in Aggressive Lymphomas. <i>Blood</i> , 2018, 132, 5401-5401.	0.6	1
383	Ibrutinib Therapy in Patients with Waldenstrom Macroglobulinemia: Outcomes Outside of Clinical Trial Setting. <i>Blood</i> , 2018, 132, 1606-1606.	0.6	1
384	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2884-2884.	0.6	1
385	Prognosis of Patients with Waldenström Macroglobulinemia: A Simplified Model. <i>Blood</i> , 2018, 132, 4152-4152.	0.6	1
386	Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study. <i>Blood</i> , 2021, 138, 1415-1415.	0.6	1
387	Central Nervous System Involvement By Mantle Cell Lymphoma. <i>Blood</i> , 2021, 138, 2426-2426.	0.6	1
388	Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. <i>Blood</i> , 2021, 138, 2429-2429.	0.6	1
389	Time to Refractory Status Defines Subsets of Primary Refractory Diffuse Large B-Cell Lymphoma with Distinct Outcomes. <i>Blood</i> , 2021, 138, 2524-2524.	0.6	1
390	Central Nervous System (CNS) Involvement of Richter Transformation: A Single Center Experience. <i>Blood</i> , 2020, 136, 3-4.	0.6	1
391	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 26-27.	0.6	1
392	PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. <i>Blood Cancer Journal</i> , 2022, 12, 78.	2.8	1
393	Phase II trial assessing safety and preliminary efficacy of high-dose intravenous ascorbic acid in patients with TET2-mutant clonal cytopenias of undetermined significance.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7076-TPS7076.	0.8	1
394	PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design. <i>Leukemia and Lymphoma</i> , 0, , 1-16.	0.6	1
395	Standard Approaches to Relapsed Indolent Non-Hodgkin's Lymphoma. <i>Seminars in Hematology</i> , 2007, 44, S12-S17.	1.8	0
396	The use of ⁹⁰ yttrium-ibritumomab tiuxetan in patients on dialysis: what do we know regarding its pharmacokinetics?. <i>Leukemia and Lymphoma</i> , 2013, 54, 2586-2587.	0.6	0

#	ARTICLE	IF	CITATIONS
397	The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma. <i>Haematologica</i> , 2021, 106, 2261-2264.	1.7	0
398	Impact of time to relapse and response to salvage therapy on post autologous stem cell transplant outcomes in relapsed or refractory diffuse large B-cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19501-e19501.	0.8	0
399	Diffuse large B-cell lymphoma with leukemic involvement.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19552-e19552.	0.8	0
400	The Role of CXCR4 Inhibitors as Novel Antiangiogenesis Agents in Cancer Therapy.. <i>Blood</i> , 2004, 104, 1296-1296.	0.6	0
401	Clinical and Biological Correlates of CD45 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma.. <i>Blood</i> , 2004, 104, 3362-3362.	0.6	0
402	APRIL Promotes Survival and Proliferation of T Cells: Implications for T-Cell Lymphoma.. <i>Blood</i> , 2004, 104, 2652-2652.	0.6	0
403	PS-341 Induces Selective Radiosensitization of Multiple Myeloma Cells.. <i>Blood</i> , 2004, 104, 2478-2478.	0.6	0
404	Elevated BlyS Levels in Patients with Familial and Sporadic B-CLL: Correlation with BlyS Polymorphisms.. <i>Blood</i> , 2004, 104, 964-964.	0.6	0
405	Lack of Increased Clinical Efficacy When Interleukin-12 Is Added to Rituximab in B-Cell Lymphoma Patients Is Related to Inadequate Delivery of the Cytokine to the Sites of Lymphoma.. <i>Blood</i> , 2004, 104, 1397-1397.	0.6	0
406	Proteomic Analysis of Multiple Myeloma Identifies Potential Targets for Drug Therapy.. <i>Blood</i> , 2004, 104, 2446-2446.	0.6	0
407	Proteomic Analysis of Targeted Therapeutic Agents in Multiple Myeloma (MM).. <i>Blood</i> , 2004, 104, 4299-4299.	0.6	0
408	Proteomic Analysis of Waldenstrom Macroglobulinemia (WM) and IgM Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS) Identifies Potential Targets for Drug Therapy.. <i>Blood</i> , 2004, 104, 787-787.	0.6	0
409	Comparison of Early and Late Autologous Stem Cell Transplants for Multiple Myeloma: A Single Institution Experience.. <i>Blood</i> , 2004, 104, 928-928.	0.6	0
410	Oncolytic Measles Virus Selectively Targets CD46 Overexpression on Myeloma Cells.. <i>Blood</i> , 2004, 104, 2392-2392.	0.6	0
411	Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin®) Induces Long-Term Responses in Patients with Relapsed or Refractory Follicular Lymphoma (FL).. <i>Blood</i> , 2004, 104, 2629-2629.	0.6	0
412	Intratumoral CD4+CD25+ Regulatory T-Cell-Mediated Suppression of Infiltrating CD4+ T-Cells in B-Cell Non-Hodgkin Lymphoma.. <i>Blood</i> , 2005, 106, 3312-3312.	0.6	0
413	Intratumoral Treg Cells Completely Inhibit the Induction and Function of Tumor-Infiltrating CD8+ T-Cells in B-Cell NHL.. <i>Blood</i> , 2005, 106, 3311-3311.	0.6	0
414	Prognostic Factors and Survival of Patients with Primary Mediastinal Large B-Cell Lymphoma.. <i>Blood</i> , 2005, 106, 4698-4698.	0.6	0

#	ARTICLE	IF	CITATIONS
415	Absolute Lymphocyte Count Recovery during Standard Chemotherapy Predicts Superior Survival and Is Independent of the Hasenclever Index for Hodgkin's Disease.. Blood, 2005, 106, 2667-2667.	0.6	0
416	Targeting V α -4 Reduces Cell Adhesion Mediated Drug Resistance in Chronic Lymphocytic Leukemia: Rationale for Anti V α -4 Therapy.. Blood, 2005, 106, 1182-1182.	0.6	0
417	A Preliminary Report of a Phase I Study of Zevalin [®] Using a Modified Treatment Regimen for Relapsed or Refractory CD20+ B-Cell Follicular or Transformed Non-Hodgkin's Lymphoma (NHL).. Blood, 2005, 106, 4798-4798.	0.6	0
418	Treatment of Diuretic Refractory Pleural Effusions with Bevacizumab in Four Patients with Primary Systemic Amyloidosis (AL).. Blood, 2006, 108, 5125-5125.	0.6	0
419	Absolute Lymphocyte Count Predicts Overall Survival in T Cell Lymphomas.. Blood, 2006, 108, 3878-3878.	0.6	0
420	Clinical and Biologic Studies in Smoldering/Indolent Multiple Myeloma (SMM/IMM) Suggest That Therapies That Specifically Inhibit IL-6 Production Are More Effective at Targeting the Proliferative Myeloma Component Than Apoptosis Inducing Agents.. Blood, 2006, 108, 3500-3500.	0.6	0
421	Improved Survival in Patients with Peripheral T Cell Lymphoma, Unspecified Following High-Dose Therapy and Stem Cell Transplantation: A Retrospective Review of a Single Institution's Experience.. Blood, 2006, 108, 3062-3062.	0.6	0
422	A Large Scale Evaluation of Genetic Variation in Immune and Inflammation Genes and Risk of Non-Hodgkin Lymphoma.. Blood, 2006, 108, 817-817.	0.6	0
423	Absolute Lymphocyte Count Is Independent of the Anaplastic Lymphoma Kinase and Predicts Survival in Primary Anaplastic Large Cell Lymphoma.. Blood, 2007, 110, 1335-1335.	0.6	0
424	Statin Use and Risk of Non-Hodgkin Lymphoma (NHL): Preliminary Results from the Mayo Clinic Case-Control Study.. Blood, 2007, 110, 2615-2615.	0.6	0
425	Malignant B Cells Skew the Balance between Treg Cell and TH17 Cell Differentiation in B-Cell Non-Hodgkin Lymphoma (NHL).. Blood, 2007, 110, 1347-1347.	0.6	0
426	Superiority of Lenalidomide-Dexamethasone Versus Thalidomide-Dexamethasone as Initial Therapy for Newly Diagnosed Multiple Myeloma.. Blood, 2009, 114, 3884-3884.	0.6	0
427	Vitamin D Deficiency Is Associated with Inferior Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma.. Blood, 2009, 114, 1952-1952.	0.6	0
428	Asymptomatic Amyloidosis at the Time of Diagnostic Bone Marrow Biopsy in Newly Diagnosed Patients with Multiple Myeloma and Smoldering Multiple Myeloma.. Blood, 2009, 114, 2803-2803.	0.6	0
429	MYC Translocations Are Associated with Poor Overall Survival in DLBCL Patients in Both the Chemotherapy and Immunochemotherapy Eras.. Blood, 2009, 114, 443-443.	0.6	0
430	Increased Immune Suppressive CD14+ hla-DRneg Circulating Monocytes Are Found in Aggressive Non-Hodgkin's Lymphoma and Correlated with Increased Arginase I Level.. Blood, 2009, 114, 970-970.	0.6	0
431	A Newly Identified Translocation t(X;14)(p11;q32) In MALT Lymphoma Involving IGHS and GPR34 Reveals A Novel Role for GPR34 In Cell Growth and Tumor Development. Blood, 2010, 116, 1999-1999.	0.6	0
432	Dissecting the Genetic Basis of Marginal Zone Lymphoma Reveals a Predilection for NF-Kb Activation by Clonal MZL Located at Extranodal Sites. Blood, 2010, 116, 4160-4160.	0.6	0

#	ARTICLE	IF	CITATIONS
433	Vitamin D Insufficiency and Prognosis In Chronic Lymphocytic Leukemia (CLL). Blood, 2010, 116, 2408-2408.	0.6	0
434	Monoclonal and Polyclonal Serum Free Light Chains and Clinical Outcome In Chronic Lymphocytic Leukemia. Blood, 2010, 116, 2409-2409.	0.6	0
435	GLI2, An Effector of the Hedgehog Pathway, Is a Novel Regulator of IL6 Oncogenic Function In the Tumor Microenvironment. Blood, 2010, 116, 613-613.	0.6	0
436	Elevation of Serum Free Light Chains Are Common In Lymphoma and Associated with Poor Event Free and Overall Survival. Blood, 2010, 116, 4136-4136.	0.6	0
437	A BAFF-R Mutation Associated with Non-Hodgkin Lymphoma Exhibits Altered TRAF Binding and Reveals New Insights Into Proximal BAFF-R Signaling. Blood, 2010, 116, 468-468.	0.6	0
438	Interactions with the Microenvironment Protect Lymphoma B-Cells From Rituximab Induced Apoptosis and Could Represent a Therapeutic Target. Blood, 2010, 116, 3115-3115.	0.6	0
439	Phase II Clinical Trial of Denileukin Diftitox In Combination with Rituximab In Previously Untreated Follicular B-Cell Non-Hodgkin's Lymphoma. Blood, 2010, 116, 2862-2862.	0.6	0
440	Germline Variation in TNF and NF-Kappa B Pathways and Prognosis In Mantle Cell Lymphoma. Blood, 2010, 116, 4127-4127.	0.6	0
441	IL-21 in the Bone Marrow Microenvironment Contributes to IgM Secretion and Proliferation of Malignant Cells in Waldenstrom's Macroglobulinemia. Blood, 2011, 118, 770-770.	0.6	0
442	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis Is Independent of the Cell of Origin in Predicting Survival in Diffuse Large B-Cell Lymphoma,. Blood, 2011, 118, 3652-3652.	0.6	0
443	Elevated Serum IL-10 Levels in Patients with Diffuse Large B Cell Lymphoma: A Mechanism of Aberrant JAK2 Kinase Activation. Blood, 2011, 118, 960-960.	0.6	0
444	Utility of Stem Cell Collection in Anticipation of Future Need for Autologous Stem Cell Transplant in Follicular Lymphoma Patients. Blood, 2011, 118, 1926-1926.	0.6	0
445	Risk of Transformation of Follicular Lymphoma to High Grade Lymphoma After Radioimmunotherapy: A Prospective Observational Single Institutional Experience. Blood, 2011, 118, 1572-1572.	0.6	0
446	Peripheral Blood Lymphocyte/Monocyte Ratio At Diagnosis and Survival in Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,. Blood, 2011, 118, 3642-3642.	0.6	0
447	Phase I, Multicenter, Open Label, Dose Escalation of 90yttrium-Ibritumomab Tiuxetan Radioimmunotherapy Using a Modified Regimen for Relapsed or Refractory Follicular or Transformed CD20+ B-Cell Lymphoma. Blood, 2011, 118, 1648-1648.	0.6	0
448	Silencing of SHP1 Is Frequent in Phospho-STAT3 Positive Diffuse Large Cell Lymphoma and This Silencing Is Independent of Methylation of CpG Islands,. Blood, 2011, 118, 3678-3678.	0.6	0
449	Phase I Trial of a Novel Combination of An HDAC Inhibitor (LBH589) and An mTOR Inhibitor (RAD001) in Lymphoid and Plasma Cell Malignancies. Blood, 2011, 118, 2682-2682.	0.6	0
450	Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia.. Journal of Clinical Oncology, 2012, 30, 8043-8043.	0.8	0

#	ARTICLE	IF	CITATIONS
451	LR-CD: Lenalidomide combination therapy for untreated low-grade B-cell NHL.. Journal of Clinical Oncology, 2012, 30, 8053-8053.	0.8	0
452	Outcomes of Patients with POEMS Syndrome Treated Initially with Radiation. Blood, 2012, 120, 448-448.	0.6	0
453	Diffuse Large B-Cell Transformation in Nodular Lymphocyte Predominant Hodgkin Lymphoma: Incidence, Risk Factors and Outcomes After a Forty-Year Experience From a Single Institution. Blood, 2012, 120, 1525-1525.	0.6	0
454	Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab, Rituximab, and PGG Beta Glucan: A Phase I Clinical Trial. Blood, 2012, 120, 1792-1792.	0.6	0
455	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Blood, 2012, 120, 684-684.	0.6	0
456	Expression of MYC but Not pSTAT3 Is an Adverse Prognostic Factor for Diffuse Large B Cell Lymphoma (DLBCL) Treated with Epratuzumab/R-CHOP. Blood, 2012, 120, 1575-1575.	0.6	0
457	LR-CD: Efficacy of Combination Therapy with Lenalidomide for Untreated Indolent B-Cell NHL.. Blood, 2012, 120, 2741-2741.	0.6	0
458	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. Blood, 2012, 120, 1563-1563.	0.6	0
459	Importance of Achieving Sustained Stringent Complete Response (sCR) Following Autologous Stem Cell Transplantation in Multiple Myeloma. Blood, 2012, 120, 1988-1988.	0.6	0
460	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During ABVD Treatment Cycles Predicts Clinical Outcomes in Classical Hodgkin Lymphoma (HL).. Blood, 2012, 120, 2634-2634.	0.6	0
461	Expression but Not Promoter Hypermethylation of the Tyrosine Phosphatase PTPN6 Is Associated with Activated STAT3 and Inferior Prognosis in Diffuse Large B Cell Lymphoma Molecular Subtypes.. Blood, 2012, 120, 2655-2655.	0.6	0
462	Elevated Soluble IL-2Ra Levels Are Associated With Inferior Outcome and Is Independent Of MIPI Score in Patients With Mantle Cell Lymphoma. Blood, 2013, 122, 4256-4256.	0.6	0
463	An Effective and Tolerable Chemoimmunotherapy Regimen For Relapsed/Refractory and Very-High Risk Chronic Lymphocytic Leukemia Combining Alemtuzumab With Pentostatin and Low Dose Rituximab. Blood, 2013, 122, 1641-1641.	0.6	0
464	Complement Factor H Related Protein 1 (CFHR1) Serum Level Correlates With Event-Free Survival In Follicular Lymphoma Patients Treated With Rituximab. Blood, 2013, 122, 4288-4288.	0.6	0
465	Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma. Blood, 2013, 122, 1774-1774.	0.6	0
466	GATA-3 Expression Promotes IL-10 Production, Alternative Macrophage Polarization, and Identifies a Subset Of High-Risk PTCL, NOS. Blood, 2013, 122, 841-841.	0.6	0
467	Peripheral Blood Absolute Lymphocyte/Monocyte Ratio Recovery During RCHOP Treatment Cycles Predicts Clinical Outcomes In Diffuse Large B-Cell Lymphoma. Blood, 2013, 122, 4306-4306.	0.6	0
468	Prognostic Correlates and Outcomes of Relapsed T-Cell Acute Lymphoblastic Leukemia/Lymphoma: An Analysis of 41 Consecutive Patients. Blood, 2015, 126, 3730-3730.	0.6	0

#	ARTICLE	IF	CITATIONS
469	Tissue Is the Issue: Accuracy of PET Imaging to Detect Bone Marrow Clearance in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 3947-3947.	0.6	0
470	Survival Trends in Adult T-Acute Lymphoblastic Leukemia / Lymphoma (ALL), a Comparative Analysis of 92 Patients By Year of Diagnosis. <i>Blood</i> , 2015, 126, 2490-2490.	0.6	0
471	Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 1501-1501.	0.6	0
472	The Adverse Impact of Age and Central Nervous System Involvement on Survival in Adult T-ALL, an Analysis of 92 Consecutive Patients. <i>Blood</i> , 2015, 126, 4993-4993.	0.6	0
473	Natural History of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2015, 126, 1456-1456.	0.6	0
474	Outcomes of DLBCL Patients Entering Surveillance (without maintenance) after Immunochemotherapy in a Large Observational Study. <i>Blood</i> , 2016, 128, 3036-3036.	0.6	0
475	Survival Trends in Young Patients with Waldenstrom Macroglobulinemia: Over 5 Decades of Experience. <i>Blood</i> , 2016, 128, 1810-1810.	0.6	0
476	Lenalidomide Plus R-CHOP (R2CHOP) in Patients with Follicular Lymphoma: Data from a Phase 1/2 Study. <i>Blood</i> , 2016, 128, 5322-5322.	0.6	0
477	No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era. <i>Blood</i> , 2016, 128, 107-107.	0.6	0
478	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 2935-2935.	0.6	0
479	Lenalidomide in Combination with Standard R-CHOP Overcomes the Negative Prognostic Value of Peripheral Blood Absolute Lymphocyte/Monocyte Ratio at Diagnosis and during Treatment in Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018, 132, 4139-4139.	0.6	0
480	Role of Systemic High-Dose Methotrexate and Combined Approaches in the Management of Vitreoretinal Diffuse Large B-Cell Lymphoma: A Single Center Experience 1990-2018. <i>Blood</i> , 2018, 132, 574-574.	0.6	0
481	Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma (MM), Acute Myeloid Leukemia (AML), and T-Cell Neoplasms (TCL). <i>Blood</i> , 2018, 132, 3268-3268.	0.6	0
482	A Longitudinal Toxicity over Time (ToxT) Analysis of Bortezomib When Added to Bendamustine-Rituximab (BR) in Previously Untreated High Risk (HR) Follicular Lymphoma (FL) from in E2408. <i>Blood</i> , 2018, 132, 4157-4157.	0.6	0
483	Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era. <i>Blood</i> , 2018, 132, 4140-4140.	0.6	0
484	Waldenström Macroglobulinemia with Excess Plasma Cells: Is It a Distinct Entity?. <i>Blood</i> , 2019, 134, 1532-1532.	0.6	0
485	Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R2-CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HROoL) Analysis of the International Robust Study. <i>Blood</i> , 2019, 134, 3475-3475.	0.6	0
486	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. <i>Blood</i> , 2019, 134, 1480-1480.	0.6	0

#	ARTICLE	IF	CITATIONS
487	Distal Enhancer Elements in ASXL1-Mutant Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2019, 134, 2981-2981.	0.6	0
488	Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures. <i>Blood</i> , 2019, 134, 1710-1710.	0.6	0
489	Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design. <i>Blood</i> , 2019, 134, 4101-4101.	0.6	0
490	An Analysis of Virus Amplification and Antitumor Responses in T-Cell Lymphoma Patients Treated with Voyager-V1 (VSV-IFN β -NIS). <i>Blood</i> , 2021, 138, 1333-1333.	0.6	0
491	Mismatch-Repair Deficiency in Follicular Lymphoma Tumors Is Common and Associated with a Favorable Overall Survival. <i>Blood</i> , 2021, 138, 3523-3523.	0.6	0
492	Characteristics, Management and Outcomes of Patients with Intravascular Lymphoma: A Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 1452-1452.	0.6	0
493	PET2 Response Associated with Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: Results of Two Independent Prospective Cohorts. <i>Blood</i> , 2021, 138, 2508-2508.	0.6	0
494	Impact of Double Hit Lymphoma and Cell of Origin in the Risk of Central Nervous System Relapse in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 1439-1439.	0.6	0
495	Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients with Multiple Myeloma with Extramedullary Disease or Plasma Cell Leukemia. <i>Blood</i> , 2020, 136, 34-35.	0.6	0
496	Hypomagnesemia Is Associated with an Increased Risk of Failure in Patients Diffuse Large B-Cell Lymphoma Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2020, 136, 21-21.	0.6	0
497	Salicylates Potentiate and Broaden CRM1 Inhibitor Anti-Tumor Activity Via S-Phase Arrest and Impaired DNA-Damage Repair. <i>Blood</i> , 2020, 136, 17-18.	0.6	0
498	Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2020, 136, 36-37.	0.6	0
499	The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma. <i>Blood</i> , 2020, 136, 39-40.	0.6	0
500	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. <i>Blood</i> , 2020, 136, 17-18.	0.6	0
501	Lenalidomide/RCHOP (R2CHOP) Produces High Response Rates and Overall Survival in New, Untreated Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma- Results from MC078E. <i>Blood</i> , 2020, 136, 47-48.	0.6	0
502	Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care. <i>JCO Oncology Practice</i> , 2022, , OP2100789.	1.4	0
503	Methylated DNA markers in early detection of lymphoma: Discovery, validation, and clinical pilot.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7562-7562.	0.8	0
504	Insurance-based disparities in Waldenstrom Macroglobulinemia: An NCDB analysis.. <i>Journal of Clinical Oncology</i> , 2022, 40, e19562-e19562.	0.8	0